Background {#Sec1}
==========

The incidence of pancreatic ductal adenocarcinoma (PDA) continues to increase. In 2017, an estimated 53670 new cases (female: 25700; male: 27970) of pancreatic cancer were diagnosed within the US and 43090 individuals (female: 20790; male: 22300) were expected to die of the tumor \[[@CR1]\]. Primary tumor resection (PTR) is the only curative modality, while more than 80% of tumors were unresectable when present \[[@CR2]\]. The 5-year survival of patients with PDA after surgery is approximately 20% (the median survival is 15--23 months) \[[@CR3]--[@CR8]\].

According to American Joint Committee on Cancer (AJCC) classification version 6, patients with stage III PDA (tumors involved celiac axis and/or superior mesenteric artery) can be divided into borderline resectable and unresectable, depending on the extent of the tumor encasement of major vessels \[[@CR2], [@CR5], [@CR6]\]. Previously, chemoradiotherapy has been carried out to reduce the risk of a positive surgical margin and distant metastasis \[[@CR2], [@CR4], [@CR9]\]. Since the FOLFIRINOX regimen (irinotecan, oxaliplatin, leucovorin, and fluorouracil) was introduced in 2011 by a prospective randomized controlled trial \[[@CR10]\], it has been reported to result in objective response rates that were 2--3 fold higher than other regimens in PDA \[[@CR11]\]. Several studies have confirmed that a large number of cases even with locally advanced and unresectable PDA can be converted to be resectable by FOLFIRINOX \[[@CR12]--[@CR14]\].

Previous publications have reported a discrepant overall survival of PDA patients with advanced disease undergoing PTR and vascular reconstruction (the median survival ranged from 12 to 35 months) \[[@CR15]--[@CR18]\]. Owing to the varying outcomes regarding to the long-term survival of underline resectable PDA receiving PTR, we designed a population-based cohort study to explore the independent role of PTR in patients with stage III PDA (S-III PDA). We utilized an instrumental variable (IV) analysis to determine variation in outcomes across geographical areas that were different in PTR rates. The IV analysis is aimed to control for potential unknown confounding factors in decision making for surgeries \[[@CR19], [@CR20]\]. In the present study, PTR rates in various Health Service Areas (HSA) was employed as our instrument. The treatment option (PTR or non-PTR) for marginal patients (those with a borderline or uncertain need for PTR) may be affected by preferences, beliefs, or surgical skills of surgeons in their HSAs. Patients with S-III PDA would be performed PTR in a high-use HSA, while not in a low-use HSA \[[@CR21], [@CR22]\]. The coefficient in the IV analysis represents the adjusted treatment effect for the marginal population rather than the average treatment effect \[[@CR21]\].

Methods {#Sec2}
=======

Patient selection {#Sec3}
-----------------

Surveillance, Epidemiology, and End Results (SEER) 18 database for 2004 through 2014 was retrieved for this study ([seer.cancer.gov/about/overview.html](http://seer.cancer.gov/about/overview.html)). The SEER population-based cancer registries covers approximately 28% of the US population, which collects data of tumor incidence, demographics, tumor characteristics and patient survival. Firstly, 107544 patients with PDA was identified based on the pathological diagnosis. The ICD-O-3 (International Classification of Diseases for Oncology, 3rd Edition) site code is C25 and histologic type codes are 8140, 8500, 8010, 8000, 8480, 8481, 8490, 8255, 8021, 8020, 8521, 8141, 8022, 8144. Tumor, node, and metastasis stage of PDA in SEER was based on AJCC stage version 6. The flow diagram of patient selection is shown in Fig. [1](#Fig1){ref-type="fig"}. Finally, a total of 4322 cases with stage III PDA were included in the analysis. The following codes related to PDA treatment were selected: PTR: 30 (partial pancreatectomy), 35--37 (Whipple), 40 (whole pancreatectomy), 60 (whole pancreatectomy with subtotal gastrectomy/duodenectomy), 70 (an extended pancreatoduodenectomy) and 80 (pancreatectomy, NOS); none surgical treatment: 0. This study has been approved by the Institutional Review Board at the West China Hospital. All patient data from SEER database is public available and anonymous.Fig. 1Flowchart representing selection process of patients included in this study

Statistical analyses {#Sec4}
--------------------

Continuous data are shown as mean ± SD and categorical variables are presented as number (%). The continuous variable was examined by t-test or Kruskal-Wallis H test the categorical data was tested by Chi-square test or Fisher's exact test. Overall survival (OS) and disease-specific survival (DSS) were the primary endpoints. The former was defined as the time from the date of treatment to the date of death with any cause and the latter was defined as interval until death caused by PDA. The Kaplan-Meier method was used to analyze survival data (compared by the log-rank test). Multivariable analyses were performed by the Cox proportional hazards regressions. Based on previous study \[[@CR23]\], the interaction tests were also carried out to identify the interactive factors influencing the relationship between treatment methods and survival.

To further adjust for potential baseline confounding factors, the propensity score matching (PSM) was carried out according to the following parameters: sex, age, race, year of diagnosis, tumor differentiation, tumor size, and chemotherapy. Cases with PTR were matched to those without PTR with a matching ratio of 1:3. The nearest-neighbor PSM was performed by logistic regression.

PTR rates in HSAs were utilized as an IV. In this study, the PTR rate in HSAs is a qualified instrument because it is highly associated with the probability of a patient's exposure to primary tumor resection (F statistic \> 10) and is also not related to patient survival. In addition, covariate balance across quintiles was also examined. We did not include patients living in HSAs with fewer than 20 patients, given the difficulty to confirm the PTR rates in those HSAs \[[@CR24]\]. The two-stage residual inclusion (2SRI) method was utilized for instrumental variable analyses \[[@CR25]\].

Results {#Sec5}
=======

Patient demographics {#Sec6}
--------------------

A total of 4322 S-III PDA patients including 552 (12.8%) who underwent PTR, 3770 (87.2%) without PTR, were identified. Table [1](#Tab1){ref-type="table"} displayed the general demographics of the final cohort of 4322 S-III PDA patients with available variables. The mean age of patients undergoing PTR and none was 64.6 and 66.7 years, respectively. Compared with the non-surgery group, the PTR group had more pancreatic head tumor (79.3% vs. 70.9%) and smaller tumor size (38.5 ± 16.3 mm vs. 41.0 ± 15.4 mm). The other clinicopathologic characteristics including sex, race and number of patients receiving chemotherapy showed no statistically significance between PTR and non-surgery groups (all *P* \> 0.05).Table 1Clinical features of the included patients with PDAVariableBefore PSMAfter PSMNone (*n* = 3770)PTR (*n* = 552)*P* valueNone (*n* = 720)PTR (*n* = 240)*P* valueAge (years)66.7 ± 11.364.6 ± 10.5\< 0.00167.4 ± 11.167.2 ± 10.20.777Sex0.5100.911 Female1887 (50.1%)268 (48.6%)361 (50.1%)122 (50.8%) Male1883 (49.9%)284 (51.4%)359 (49.9%)118 (49.2%)Race0.5280.161 White2968 (78.7%)445 (80.6%)563 (78.2%)197 (82.1%) Black463 (12.3%)59 (10.7%)93 (12.9%)20 (8.3%) Other339 (9.0%)48 (8.7%)64 (8.9%)23 (9.6%)Primary tumor site in pancreas\< 0.0010.463 Head2672 (70.9%)438 (79.3%)501 (69.6%)173 (72.1%) Body and tail1080 (28.6%)116 (19.2%)219 (30.4%)67 (27.9%)Tumor size (mm)41.0 ± 15.438.5 ± 16.3\< 0.00144.9 ± 16.745.6 ± 18.60.558Tumor differentiation\< 0.0010.197 I178 (4.7%)52 (9.4%)57 (7.9%)17 (7.1%) II402 (10.7%)223 (40.4%)153 (21.2%)56 (23.3%) III421 (11.2%)163 (29.5%)168 (23.3%)53 (22.1%) IV26 (0.7%)3 (0.5%)1 (0.1%)3 (1.2%)Chemotherapy0.2720.228 No/unknown2960 (78.5%)422 (76.4%)608 (84.4%)194 (80.8%) Yes810 (21.5%)130 (23.6%)112 (15.6%)46 (19.2%)Data are shown as mean ± SD or n (%). PTR, primary tumor resection. Tumor differentiation: I, well-differentiated; II, moderate- differentiated; III, poor-differentiated; IV, un-differentiated

Multivariable analyses {#Sec7}
----------------------

In multivariable analyses, we included a total of 4322 patients with known prognostic data. The mean overall survival time (in the total cohort) for patients who underwent PTR and patients undergoing non-surgery were 23.9 months and 14.5 months, respectively. The mean DSS time for cases after PTR and none were 23.9 and 15.4 months, respectively. Patients with PTR had longer OS (*P* \< 0.001) and DSS (*P* \< 0.001) compared to patients with non-surgery treatment (Fig. [2](#Fig2){ref-type="fig"}a and c).Fig. 2**a**: Overall survival analysis for patients undergoing PTR and none in non-adjusted population. **b**: Overall survival analysis for patients after PTR and none in propensity score matched population. **c**: Disease-specific survival analysis for patients undergoing PTR and none in non-adjusted population. **d**: Disease-specific survival analysis for patients after PTR and none in propensity score matched population

In the cohort for multivariable analyses (OS: *n* = 4322; DSS: *n* = 4055), after adjusting for potential confounding factors, a clear prognostic advantage of PTR was observed in OS (HR, 0.59; 95% CI, 0.53 to 0.66; *P* \< 0.001) and DSS (HR, 0.57; 95% CI, 0.51 to 0.65; *P* \< 0.001) compared to patients after non-surgery therapy (Table [2](#Tab2){ref-type="table"}).Table 2Association of PTR with patient overall survival in locally advanced PDA patientsOSDSSNumberHR (95%CI)*P* valueNumberHR (95% CI)*P* valueNon-adjusted43220.61 (0.55, 0.68)\< 0.00140550.60 (0.54, 0.66)\< 0.001Multivariable adjusted model\*43220.59 (0.53, 0.66)\< 0.00140550.57 (0.51, 0.65)\< 0.001Matched on propensity score9600.59 (0.50, 0.69)\< 0.0019600.57 (0.47, 0.67)\< 0.001Regression adjusted with propensity score Propensity score, continuous43220.61 (0.55, 0.67)\< 0.00140550.61 (0.54, 0.68)\< 0.001 Propensity score, quintile43220.62 (0.56, 0.69)\< 0.00140550.60 (0.53, 0.67)\< 0.001PTR was the reference (HR: 1). Data are shown as HR (95% CI) *P* value. \*Adjusted model was adjusted for: age, race, sex, year of diagnosis, tumor differentiation, tumor size, tumor location and chemotherapy

Instrumental variable analysis {#Sec8}
------------------------------

To be valid, an instrumental variable must meet two conditions: 1) the variable must be highly associated with the treatment of interest (in this study receipt of PTR); and 2) the instrumental variable cannot be related to the outcomes (in this study survival) except through its effect on the treatment received \[[@CR26]\].

The average PTR rate in HSAs fluctuated from a low of 16% (quintile 1) to a high of 27% (quintile 5). The F-statistics was 3325.8 (*P* \< 0.001), indicating that the instrument was strongly related to the treatment. In addition, in a standard COX regression, no significant correlation was observed between the IV and OS (HR 1.18, 95% CI 0.27--5.05, *P* = 0.827). We divided patients into quintiles according to the proportion of cases within each HSA who underwent PTR (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Most of the clinicopathologic features were balanced across quintiles. Consequently, these observations suggest that HSA PTR rate meets the two requirements for a valid instrument.

For patients with S-III PDA, the salutary benefit of PTR in survival was not observed in the 2SRI model. In IV analysis, results indicated that patients who underwent PTR had similar OS (HR 0.74, 95% CI 0.34--1.61, *P* = 0.448) and DSS (HR 0.86, 95% CI 0.38--1.94, *P* = 0.719) after adjusting confounding factors (Table [3](#Tab3){ref-type="table"}).Table 3Instrumental variable analysis of the impact of PTR on survival for patients with stage III locally advanced PDA in 2SRI IV modelOS (*n* = 4322)DSS (*n* = 4055)HR95% CI*P*-valueHR95% CI*P*-valuePTR vs. none0.7410.342, 1.6070.4480.8620.384--1.9350.719Age, years1.0131.010--1.017\< 0.0011.0151.011--1.018\< 0.001Sex, male vs. female1.1121.043--1.1870.0011.1041.032--1.1800.004Race Black vs. White1.0800.974--1.1970.1461.0850.974--1.2090.137 Other vs. White0.9780.872--1.0970.7000.9900.878--1.1160.871Primary tumor site in pancreas Body vs. head0.9550.874--1.0450.3170.9540.870--1.0460.314 Tail vs. head1.0510.886--1.2460.5700.9940.829--1.1910.948Tumor size, cm1.0031.001--1.005\< 0.0011.0041.002--1.007\< 0.001Tumor differentiation II vs. I1.1570.981--1.3660.0841.1961.005--1.4240.044 III vs. I1.5751.334--1.860\< 0.0011.6281.368--1.938\< 0.001 IV vs. I1.8061.181--2.7620.0061.8111.171--2.7990.008Year of diagnosis, 2010--2014 vs. 2004--20090.9870.981--0.994\< 0.0010.9840.977--0.990\< 0.001OS, overall survival; DSS, disease-specific survival; HR, hazard ratios; CI, confidence interval. Tumor differentiation: I, well-differentiated; II, moderate- differentiated; III, poor-differentiated; IV, un-differentiated

Subgroup analyses {#Sec9}
-----------------

In IV analyses stratified by chemotherapy, we found that the similar effects of PTR vs. none on patient survival were consistent across both subgroups (Table [4](#Tab4){ref-type="table"}). In IV analyses, patients in the PTR group receiving chemotherapy had similar OS (HR 0.43, 95% CI 0.09--2.15, *P* = 0.304) and DSS (HR 0.56, 95% CI 0.10--3.14, *P* = 0.508) compared to patients in the non-PTR group receiving chemotherapy. In IV analyses stratified by tumor location, we found that the similar effects of PTR vs. non-PTR on survival (both OS and DSS) were consistent across all subgroups with different tumor location (Table [5](#Tab5){ref-type="table"}).Table 4Subgroup analyses according to chemotherapy (P for interaction: 0.679)No chemotherapy or unknownChemotherapyOS Non-adjusted0.58 (0.51, 0.65) \< 0.0010.67 (0.55, 0.81) \< 0.001 Adjusted  Traditional regression model0.58 (0.51, 0.66) \< 0.0010.61 (0.48, 0.76) \< 0.001  2SRI IV model1.27 (0.51, 3.13) 0.6100.43 (0.09, 2.15) 0.304DSS Non-adjusted0.55 (0.49, 0.63) \< 0.0010.67 (0.55, 0.82) \< 0.001 Adjusted  Traditional regression model0.56 (0.49, 0.64) \< 0.0010.61 (0.48, 0.77) \< 0.001  2SRI IV model1.31 (0.51, 3.34) 0.5730.56 (0.10, 3.14) 0.508PTR was the reference (HR: 1). Data are shown as HR (95%CI) *P* value. All adjusted models were adjusted for: age, race, sex, year of diagnosis, tumor location and tumor size. OS, overall survival; DSS, disease-specific survival; 2SRI, 2 stage residual inclusion; IV, instrumental variableTable 5Subgroup analyses according to tumor locationPancreatic headPancreatic bodyPancreatic tailOS Non-adjusted0.60 (0.54, 0.67) \< 0.0010.48 (0.35, 0.66) \< 0.0010.81 (0.57, 1.17) 0.264 Adjusted  Traditional regression model0.58 (0.51, 0.66) \< 0.0010.55 (0.39, 0.76) \< 0.0010.54 (0.35, 0.86) 0.009  2SRI IV model0.43 (0.12, 1.48) 0.1810.39 (0.01, 18.80) 0.6371.57 (0.01, 217.96) 0.858DSS Non-adjusted0.58 (0.52, 0.66) \< 0.0010.48 (0.34, 0.66) \< 0.0010.85 (0.58, 1.24) 0.392 Adjusted  Traditional regression model0.57 (0.50, 0.64) \< 0.0010.53 (0.37, 0.75) \< 0.0010.53 (0.32, 0.87) 0.013  2SRI IV model0.72 (0.20, 2.62) 0.6140.44 (0.01, 24.44) 0.6890.90 (0.00, 203.30) 0.970PTR was the reference (HR: 1). Data are shown as HR (95%CI) *P* value. All adjusted models were adjusted for: age, race, sex, year of diagnosis, tumor size and chemotherapy. OS, overall survival; DSS, disease-specific survival; 2SRI, 2 stage residual inclusion; IV, instrumental variable

In IV analyses stratified by the other clinicopathologic characteristics (sex, race, age, year of diagnosis and tumor size.), we found that the treatment effect of PTR (OS and DSS) was consistent across all the subgroups (data not shown).

Propensity score matched analyses {#Sec10}
---------------------------------

In the propensity-matched population, all the potential prognosis-relevant characteristics were well-balanced for most of the baseline features (Table [1](#Tab1){ref-type="table"}). In the PSM cohort, results from the univariate analysis indicated that cases with PTR had better OS (HR 0.59, 95% CI 0.50--0.69 *P* \< 0.001) and DSS (HR 0.57, 95% CI 0.47--0.67, *P* \< 0.001) compared to patients with non-surgery treatment (Table [2](#Tab2){ref-type="table"}). In the PSM-adjusted population, patients in PTR group still showed a better OS and DSS (both *P* values \< 0.001) compared to patients in non-surgery group by Kaplan-Meier method (Fig. [2](#Fig2){ref-type="fig"}b and d).

The HRs (PTR vs. none) adjusted by propensity score showed both longer OS (continuous: HR 0.61, 95% CI 0.55--0.67, *P* \< 0.001; quintile: HR 0.62, 95% CI 0.56--0.69, *P* \< 0.001) and DSS (continuous: HR 0.61, 95% CI 0.54--0.68, *P* \< 0.001; quintile: HR 0.60, 95% CI 0.53--0.67, *P* \< 0.001) associated with PTR (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec11}
==========

Pancreatic resection is associated with better outcomes for early-stage PDA. \[[@CR27]\] However, for patients with underline resectable PDA, though chemotherapy regimen such as FOLFIRINOX increased the tumor resectability, the long-term survival (OS and DSS) in this study was comparable to those receiving non-surgery treatment in IV analyses. This conclusion is inconsistent with previous studies demonstrating that S-III PDA patients had a better survival after PTR compared to those without surgery \[[@CR15], [@CR18], [@CR28]--[@CR30]\].

Among previous studies related to PTR versus non-surgical management in cases with advanced PDA, there were two randomized controlled trials (RCTs) \[[@CR28], [@CR29]\] comparing PTR versus non-surgical treatments in cases with underline resectable PDA. Both RCTs included patients with locally advanced PDA invading the serosa anteriorly or retroperitoneum posteriorly or involving the major vascular structures. One RCT enrolled cases with PDA in different location of the pancreas and another included only cases with tumor in the pancreatic head or neck. Both studies demonstrated that patients receiving PTR and vascular resection and reconstruction had longer survival compared to patients only undergoing non-surgery treatment such as chemoradiotherapy. However, both researches were at high risk of bias and only a small number of patients (47 and 51 patients in two studies, respectively) were included.

In this study, utilizing IV analyses, we concluded that patients with S-III PDA receiving PTR had a similar long-term prognosis compared to those without PTR (only receive non-surgery treatments). We have applied both traditional regression analyses and propensity score methods to explore relations between surgical methods and long-term survival. However, these analytic methods cannot adjust for unknown confounding factors \[[@CR15], [@CR26]\]. In contrast, results from IV analyses (2SRI model) were observed to be more close to outcomes from RCTs \[[@CR26]\]. Given the lack of high-quality RCTs associated with PTR vs. none for PDA patients, results of IV analyses may represent the best evidence available to guide treatment decision-making. It should be noted that IV analyses estimate the treatment effect on the marginal population rather than the average treatment effect of PTR \[[@CR19], [@CR21]\]. The marginal population represents the population that would receive PTR in a high-use HSA but not in a low-use HSA. The IV analysis does not rely on defining the specific clinical parameters of these populations. Instead, it is based on the hypothesis that patients reside randomly around hospitals and some patients are treated differently in different centers.

There are several limitations to this study. First, although we have acquired the data related to the chemotherapy from SEER database, the detailed regimens and the timing of chemotherapy were yet inaccessible. Patients without chemotherapy or with unknown data of chemotherapy accounted for nearly 80% of patients with pancreatic cancer. In addition, we cannot divide S-III PDA into borderline resectable and unresectable groups based on the extension of tumor invasion, thus we cannot assess whether patients with surgical resection was well chosen. The proportion of patients with R0 tumor resection could not be confirmed in this study. Second, patient performance status and presence of comorbidities are risk factors for patient prognosis. However, the SEER database does not provide these data, thus we cannot adjust these factors by multivariable analyses. Third, details on postoperative morbidities were extremely limited, thus we could not evaluate the influence of treatment methods to the short-term prognosis. Fourth, the observations of this study should be interpreted cautiously, due to some patients with unknown covariates in the SEER database were excluded from the analyses. Finally, even though treatment rate (PTR rate) is a useful practical IV, there remains potential for instrument-outcome confounding, such as receipt of other treatments also associated with our instrument and the outcome. In addition, IV analysis only estimates the effect on marginal population, while the marginal population excludes patients who would always or never receive PTR, focusing on PDA patients whose indications for PTR are more uncertain (Fig. [3](#Fig3){ref-type="fig"}). \[[@CR20], [@CR26], [@CR31]\]Fig. 3In **a**, the hospital performs PTR less and has a higher threshold for PTR while in **b**, the hospital performs PTR more frequently and has a lower threshold for carrying out PTR. In both hospitals, there will be a population of patients who would never be performed PTR (group "a") as well as patients who would always be performed PTR (group "c"). At the same time, there will be a group of patients who would either not be performed (group "b1") or would be performed (group "b2") PTR solely because of the hospital to which they presented. These "b" groups together are the marginal population

Conclusions {#Sec12}
===========

In conclusion, by integrating results from multivariate COX regression, PSM models and IV analysis, our study demonstrated that PTR provided similar overall and tumor-specific survival benefits in cases with stage III PDA compared to patients with palliative treatments. Further high-quality prospective randomized trials are needed to validate this conclusion and further investigations are required to identify late-stage patients suitable for PTR.

Additional file
===============

 {#Sec13}

Additional file 1:**Table S1.** Characteristics of patients by quintile of Health Services Area PTR rates. (DOCX 18 kb)
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